(Q42982914)

12 November 2017

title

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. (English)

1 reference

12 November 2017

1 reference

1 reference

P Komolmit

14

0 references

Robert Flisiak

object named as

R Flisiak

6

0 references

author name string

S Pianko

1

1 reference

12 November 2017

S Zeuzem

2

1 reference

12 November 2017

W-L Chuang

3

1 reference

12 November 2017

G R Foster

4

1 reference

12 November 2017

S K Sarin

5

1 reference

12 November 2017

C-M Lee

7

1 reference

12 November 2017

P Andreone

8

1 reference

12 November 2017

T Piratvisuth

9

1 reference

12 November 2017

S Shah

10

1 reference

12 November 2017

A Sood

11

1 reference

12 November 2017

J George

12

1 reference

12 November 2017

M Gould

13

1 reference

12 November 2017

S Thongsawat

15

1 reference

12 November 2017

T Tanwandee

16

1 reference

12 November 2017

J Rasenack

17

1 reference

12 November 2017

Y Li

18

1 reference

12 November 2017

M Pang

19

1 reference

12 November 2017

Y Yin

20

1 reference

12 November 2017

G Feutren

21

1 reference

12 November 2017

I M Jacobson

22

1 reference

12 November 2017

B2202 Study Team

23

1 reference

12 November 2017

publication date

21 March 2012

1 reference

Journal of Viral Hepatitis

12 November 2017

published in

1 reference

12 November 2017

volume

19

1 reference

12 November 2017

issue

9

1 reference

12 November 2017

page(s)

623-634

1 reference

The global burden of hepatitis C

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Epidemiology of hepatitis B and C viruses: a global overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01586.X

10.1111/J.1365-2893.2012.01586.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference